Alaa Sabry
Mansoura University, Egypt.
Title: SERUM CYSTATIN AS A MARKER OF CIS PLATINUM INDUCED ACUTE KIDNEY INJURY IN PATIENTS WITH MALIGNANCY
Biography
Biography: Alaa Sabry
Abstract
Objective:
Acute kidney injury is a common complication among patients with malignant disease receiving platinum-based chemotherapy including cisplatin and its analogues. Even mild increase in serum creatinine is associated with significant morbidity and mortality. Early biomarkers are required to detect acute kidney injury earlier in these patients for possibility of early therapeutic intervention. In this study, we investigated the ability of urinary cystatin C as an early marker of AKI induced by cisplatin and its analogues.
Methods:
The study was designed as a prospective observational study. The study included 132 patients who have malignant diseases and attended to clinical oncology and nuclear medicine department, Mansoura University Hospital, Dakahlia, Egypt for receiving platinum-based chemotherapy. Serum creatinine level was measured and Urine samples were collected in days 0, 2, 5 of each chemotherapy cycle.
Outcome:
Acute kidney injury as defined by KDIGO (2012) based on serum creatinine.
Results:
A total of 132 patients were included in the study, and 35 of them (27%) developed AKI. Urinary cystatin C levels were measured in AKI day sample and in the two preceding samples. There was significant increase in urinary cystatin C in the AKI day sample (P value = 0.018) and the preceding sample (P value = 0.009) compared to the sample taken before both of them. There was no significant increase in urinary cystatin C level in the AKI day sample compared to the preceding sample (P value = 0.433).
Conclusion:
Urinary cystatin C rises significantly before rising of serum creatinine indicating its early detective ability of cisplatin-induced AKI compared to serum creatinine.